Silencing of the CSNK2β gene by siRNA inhibits invasiveness and growth of MDA-MB-231 cells
Breast cancer is most common cancer and accounts for one-fourth of all cancer diagnoses worldwide. Treatment of triple-negative breast cancer is major challenge and identification of specific drivers is required for targeted therapies. The aim of our present study is to elucidate the therapeutic potential of CSNK2β silencing in triple negative breast cancer MDA-MB-231 cell. Methods: CSNK2β gene has been knockdown using siRNA and silencing was estimated by both real time and western blot. Cell
... ter-Glo (CTG) and colony formation assay and wound healing assay, cell cycle analysis by flow cytometry was performed to assess the role of CSNK2β in cell proliferation, migration, cell cycle, and oncogenesis. Morphological assessment of nuclear condensation, apoptosis by Hoechst staining and measurement of intracellular ROS production was examined using fluorescence microscopy. Real time PCR and western blot was done to study the expression of genes related to cell proliferation, survival, metastasis, apoptosis, and autophagy. Results: Silencing of CSNK2β in MDA-MB-231 cells resulted in decreased cell viability, colony formation, and migratory potential. Cell cycle analysis showed that growth inhibitory effect was mediated by arresting the cells in G2/M phase. Furthermore, we demonstrated that silencing of CSNK2β increased the nuclear condensation and intracellular ROS production. CSNK2β regulates the expression of BAX, Bcl-xL, caspase 3, Beclin-1, LC3-I, p-ERK, p38-α, c-Myc, MAPK, c-Jun, NF-κB, β-catenin, E2F1, PCNA. We have also shown the functional relationship between CSNK2β, PIN1, and PTOV1 by western blotting. We have first time reported that silencing CSNK2β using siRNA can inhibit invasiveness and proliferation of MDA-MB-213 cells. Conclusion: Our results suggested that CSNK2β silencing may offer future therapeutic target in triple negative breast cancer.